This document summarizes a presentation on investigating and prosecuting drug-related homicides. It discusses signs that can indicate an overdose death, such as the presence of drugs, track marks, and foam coming from the mouth. It emphasizes treating the death scene like a homicide scene by thoroughly photographing and collecting all potential evidence. This includes searching for drug packaging, needles, phones and surveillance footage. The document also outlines interviewing witnesses to build a timeline and identify the victim's source of drugs. It suggests attempting a controlled buy from suspects to obtain contemporaneous drug samples and strengthen cases.
This document summarizes presentations from two communities - Huntington, WV and Camden County, NJ - on their responses to heroin crises. It outlines programs implemented in Huntington, including a harm reduction program, centralized information system, and drug court expansion. It also discusses the region's history with prescription drug abuse and rise in heroin and associated issues like hepatitis and neonatal abstinence syndrome. Long-term strategies proposed include expanding treatment services, promoting career opportunities for those in recovery, and preventing relapse through environmental design changes.
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...OPUNITE
This document discusses strategies for investigating and prosecuting prescription drug cases. It provides an overview of how investigations are initiated, such as through complaints or reports of patient deaths. The presentation then covers investigative resources like medical records, pharmacy records, autopsy reports, toxicology results, witness interviews, and undercover operations. Details are given on obtaining search warrants, collecting evidence at clinics and storage facilities, and seizing financial records. The objectives are to identify challenges in Rx drug investigations, understand possible charges, and explain prosecuting cases against medical professionals.
This document summarizes a presentation on state and federal responses to the opioid epidemic. It discusses innovations from the Kentucky Attorney General including legislative measures targeting pill mills and heroin, programs to expand treatment and recovery, and education initiatives. It also describes the federal response through the Organized Crime Drug Enforcement Task Force (OCDETF), including their national heroin initiative targeting criminal organizations trafficking illegal opioids and heroin, and partnerships with other agencies to address public health and public safety aspects of the epidemic. The presentation outlines strategies at both state and federal levels aimed at improving access to treatment while also enforcing penalties on dealers through investigation and prosecution efforts.
The document summarizes a Heroin Response Strategy presented by experts from various High Intensity Drug Trafficking Areas. The strategy involves 3 components: 1) Establishing a regional public health and public safety information sharing network through "Points of Light" teams in each state. 2) Implementing community education and prevention programs. 3) Creating a platform for regional public health and public safety partnerships through annual symposiums. The goal is to reduce drug overdoses through enhanced collaboration between law enforcement and health agencies.
The origins of the current heroin crisis in America can be traced back to the overprescription of opioid painkillers in recent decades. As opioid prescriptions and sales increased aggressively starting in the late 1990s, so too did rates of opioid addiction, overdose deaths, and users transitioning from prescription opioids to heroin. While heroin use has been an issue in the past as well, linked to wars and social movements, the current crisis is uniquely tied to changes in opioid prescribing practices that flooded the country with highly addictive pain pills and helped reintroduce heroin as a cheaper alternative to prescription opioids.
This document discusses drug court models and the role of law enforcement in drug courts. It begins with introductions from presenters and outlines learning objectives about explaining drug court operations and benefits, how law enforcement can utilize drug courts, and identifying best practices. The following sections provide details on drug court models, including how they integrate treatment into the justice system using a non-adversarial approach. Key components of drug courts are outlined, and presenters discuss issues like prescription drug and heroin abuse as well as outcomes from drug courts in reducing recidivism and saving money. Law enforcement can play roles in prevention, addressing domestic violence, and targeting the right populations for drug court involvement through assessment.
This document provides a summary of a presentation on the risks of medical marijuana and marijuana legalization. It begins with disclosures from the presenters and outlines six learning objectives. It then discusses concerns that marijuana is addictive, especially for those who start using it early, and impacts adolescent brain development. The document notes the lack of evidence that marijuana is effective for the conditions it is claimed to treat. It also discusses the risks of increased diversion of marijuana to youth and greater social acceptance of marijuana use negatively impacting public health. The document concludes with messages on how to discuss these issues with the public.
This document provides information about an advocacy track presentation on advocating for change related to addiction issues. The presentation features Gary Mendell, founder and CEO of Shatterproof, and Kim Manlove from the Indiana Addictions Issues Coalition. They will discuss strategies for influencing legislation and how people in recovery can become advocates. The learning objectives focus on advocating for state laws on PDMP usage, explaining strategies to influence legislation, describing how people in recovery can advocate, and providing counsel as part of a treatment team. The presentation then provides details on Shatterproof's story, the overdose epidemic, solutions for different populations, and legislative accomplishments in various states related to expanding access to naloxone and mandating PDMP usage.
This document summarizes presentations from two communities - Huntington, WV and Camden County, NJ - on their responses to heroin crises. It outlines programs implemented in Huntington, including a harm reduction program, centralized information system, and drug court expansion. It also discusses the region's history with prescription drug abuse and rise in heroin and associated issues like hepatitis and neonatal abstinence syndrome. Long-term strategies proposed include expanding treatment services, promoting career opportunities for those in recovery, and preventing relapse through environmental design changes.
Web only rx16 presummit pillmills-mon_200_investigating and prosecuting pill ...OPUNITE
This document discusses strategies for investigating and prosecuting prescription drug cases. It provides an overview of how investigations are initiated, such as through complaints or reports of patient deaths. The presentation then covers investigative resources like medical records, pharmacy records, autopsy reports, toxicology results, witness interviews, and undercover operations. Details are given on obtaining search warrants, collecting evidence at clinics and storage facilities, and seizing financial records. The objectives are to identify challenges in Rx drug investigations, understand possible charges, and explain prosecuting cases against medical professionals.
This document summarizes a presentation on state and federal responses to the opioid epidemic. It discusses innovations from the Kentucky Attorney General including legislative measures targeting pill mills and heroin, programs to expand treatment and recovery, and education initiatives. It also describes the federal response through the Organized Crime Drug Enforcement Task Force (OCDETF), including their national heroin initiative targeting criminal organizations trafficking illegal opioids and heroin, and partnerships with other agencies to address public health and public safety aspects of the epidemic. The presentation outlines strategies at both state and federal levels aimed at improving access to treatment while also enforcing penalties on dealers through investigation and prosecution efforts.
The document summarizes a Heroin Response Strategy presented by experts from various High Intensity Drug Trafficking Areas. The strategy involves 3 components: 1) Establishing a regional public health and public safety information sharing network through "Points of Light" teams in each state. 2) Implementing community education and prevention programs. 3) Creating a platform for regional public health and public safety partnerships through annual symposiums. The goal is to reduce drug overdoses through enhanced collaboration between law enforcement and health agencies.
The origins of the current heroin crisis in America can be traced back to the overprescription of opioid painkillers in recent decades. As opioid prescriptions and sales increased aggressively starting in the late 1990s, so too did rates of opioid addiction, overdose deaths, and users transitioning from prescription opioids to heroin. While heroin use has been an issue in the past as well, linked to wars and social movements, the current crisis is uniquely tied to changes in opioid prescribing practices that flooded the country with highly addictive pain pills and helped reintroduce heroin as a cheaper alternative to prescription opioids.
This document discusses drug court models and the role of law enforcement in drug courts. It begins with introductions from presenters and outlines learning objectives about explaining drug court operations and benefits, how law enforcement can utilize drug courts, and identifying best practices. The following sections provide details on drug court models, including how they integrate treatment into the justice system using a non-adversarial approach. Key components of drug courts are outlined, and presenters discuss issues like prescription drug and heroin abuse as well as outcomes from drug courts in reducing recidivism and saving money. Law enforcement can play roles in prevention, addressing domestic violence, and targeting the right populations for drug court involvement through assessment.
This document provides a summary of a presentation on the risks of medical marijuana and marijuana legalization. It begins with disclosures from the presenters and outlines six learning objectives. It then discusses concerns that marijuana is addictive, especially for those who start using it early, and impacts adolescent brain development. The document notes the lack of evidence that marijuana is effective for the conditions it is claimed to treat. It also discusses the risks of increased diversion of marijuana to youth and greater social acceptance of marijuana use negatively impacting public health. The document concludes with messages on how to discuss these issues with the public.
This document provides information about an advocacy track presentation on advocating for change related to addiction issues. The presentation features Gary Mendell, founder and CEO of Shatterproof, and Kim Manlove from the Indiana Addictions Issues Coalition. They will discuss strategies for influencing legislation and how people in recovery can become advocates. The learning objectives focus on advocating for state laws on PDMP usage, explaining strategies to influence legislation, describing how people in recovery can advocate, and providing counsel as part of a treatment team. The presentation then provides details on Shatterproof's story, the overdose epidemic, solutions for different populations, and legislative accomplishments in various states related to expanding access to naloxone and mandating PDMP usage.
This document summarizes presentations from public health officials in North Carolina and Northern Kentucky on community responses to the heroin epidemic. Key points include:
- Officials from North Carolina and Northern Kentucky outlined programs and partnerships implemented in their regions to address rising rates of opioid and heroin abuse, including treatment programs, harm reduction strategies, legislation, and education initiatives.
- Data presented showed increasing rates of overdose deaths, neonatal abstinence syndrome, and infectious diseases associated with intravenous drug use such as hepatitis C in Northern Kentucky.
- Community leaders and advocates in Northern Kentucky have worked to raise awareness, pass legislation to expand access to treatment, and establish prevention and support networks to address the heroin epidemic impacting the region.
1. Co-prescribing opioids and benzodiazepines poses serious health risks like respiratory depression and increased risk of overdose death. Delaware has high rates of prescriptions for these drugs.
2. Delaware's PDMP collects prescription data that can help identify patients and providers with troubling patterns of co-prescribing to reduce risks. Regular screening and urine tests can also help address misuse.
3. PDMP data analysis found that in 2013 over 12% of individuals in Delaware filled prescriptions for both drug classes, putting them at risk. The PDMP is a valuable tool to improve prescribing practices and detect misuse.
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
This document discusses workplace issues related to prescription drug abuse and strategies for prevention. It begins with introductions of the presenters and moderators. The learning objectives are then outlined as understanding challenges of prescription drug abuse in the workplace, identifying prevention strategies, and describing programs available through SAMHSA. The document then covers topics such as the scope of prescription drug misuse among workers, risks to the workplace, prevention strategies employers can consider, and available resources from SAMHSA.
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
This presentation covered multi-media prevention strategies for issues like prescription drug overdoses. It discussed the CDC's digital Rx drug prevention campaign, best practices for digital messaging, and programs using expectancy challenge theory and media literacy education in schools. Presenters included representatives from the CDC, Media Literacy for Prevention, and the Hanley Center Foundation who discussed their work developing and implementing digital communications and single-session prevention programs.
The document discusses factors that can lead to transition from misuse of prescription opioid analgesics to heroin initiation. Through qualitative interviews with 31 individuals in New York City, four key factors were identified: 1) Use of high dose opioid analgesics; 2) Intranasal route of administration; 3) Development of physical opioid dependence; and 4) Dissolution of stigma regarding heroin in social networks. The trajectory toward heroin use was found to be similar regardless of whether opioid analgesic initiation was recreational or medical in nature.
The panel discussed two youth prevention programs - the Give Me a Reason voluntary drug testing program for parents and the This Is (Not) about Drugs prevention program implemented in schools. The Give Me a Reason program provides free at-home drug testing kits for parents to help prevent drug use among youth. The This Is (Not) about Drugs program uses a film and lesson plan to educate students about the risks of prescription opioid and heroin use with the goal of preventing first-time drug use.
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranOPUNITE
This document summarizes a presentation on a study examining how prescriber registration and use of a prescription drug monitoring program (PDMP) in Oregon impacted opioid prescribing patterns and patient outcomes. The study found that statewide opioid prescribing generally decreased over time, but prescribers who registered for the PDMP prescribed more after registering, especially those who used the PDMP most frequently. In contrast, prescribers who did not register prescribed less. Patients whose providers were all registered had lower overdose rates than those with some registered and some non-registered providers. The conclusions were that PDMPs may need refinements like mandatory use to optimize their impact on prescribing and outcomes.
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaOPUNITE
This document summarizes a presentation on preventing hepatitis C and HIV outbreaks. It includes learning objectives about informing attendees of risks of infectious disease outbreaks related to injection drug use and describing collaborations between injury and infectious disease programs. The presentation features four speakers from Indiana and North Carolina public health departments and focuses on lessons learned from an HIV outbreak in Indiana linked to injection drug use.
This document summarizes a presentation on closing treatment gaps in the health care and criminal justice systems for opioid use disorders. It introduces the presenters and moderator and provides learning objectives focused on improving identification and treatment of opioid use disorders in health care settings and strategies for improving outcomes for frequently incarcerated individuals. Disclosures are provided for the presenters stating that they have no relevant financial relationships.
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermannOPUNITE
Three prosecutors presented on investigating and prosecuting homicide by a prescribing doctor. They discussed two criminal cases that resulted in convictions, including a case in New York where a doctor was convicted of manslaughter and reckless endangerment for overprescribing opioids. They identified challenges in investigating doctor-caused deaths and how they prepared evidence showing the doctor's conduct grossly deviated from medical standards. A prosecutor from Los Angeles then discussed prosecuting a doctor for murder based on killings that occurred during the felony of over-prescribing controlled substances. Undercover operations and search warrants provided evidence of the doctor's conduct.
Rx16 federal tues_200_1_gladden_2halpin_3greenOPUNITE
This document provides information about the emerging fentanyl overdose epidemic in the United States from the national and state perspectives. It discusses the rise in fentanyl-related overdoses and seizures from 2013-2014 according to data from various sources. The learning objectives are to explain the epidemiology of the rise in fentanyl overdoses, identify lessons from an Ohio investigation, and describe one state's experience. Recommendations include improving detection of fentanyl through testing and surveillance, expanding naloxone access, and long-term efforts to reduce opioid overdoses through prescribing guidelines and treatment expansion.
Linking and mapping PDMP data can provide several benefits but also faces challenges. Linking PDMP and clinical data allows for evaluating the impact of PDMP interventions on outcomes and prescribing decisions. However, obtaining permissions and data is difficult due to legal and resource barriers. Mapping PDMP data using GIS tools in Washington identified areas for targeting overdose prevention efforts by visualizing patterns in prescribing risks, treatment availability, and overdoses. Stakeholders used these maps to guide education and funding decisions. Sustaining these tools requires ongoing funding and expanding included data sources.
This document summarizes a presentation on drugs to watch including tramadol, hydrocodone, and naloxone. It includes:
- Disclosures from presenters declaring no conflicts of interest.
- Learning objectives focused on analyzing the impact of schedule changes for tramadol and hydrocodone, educating on tramadol dangers, and evaluating pharmacist perspectives on naloxone.
- Information presented on the drugs including their classifications, potencies, risks of abuse and addiction, and impacts of rescheduling hydrocodone and tramadol in California. Data showed decreased hydrocodone prescriptions but increased tramadol and overall opioid prescriptions, as well as increased over
This document summarizes a presentation on medication-assisted treatment for opioid addiction. It discusses the history of treatment approaches, including the development of methadone and buprenorphine maintenance therapies. Studies show that agonist therapies like methadone and buprenorphine are more effective at retaining patients in treatment and reducing illicit opioid use than non-medication approaches. While both methadone and buprenorphine are effective, buprenorphine has a safer side effect profile but its effectiveness may be limited by lower monitoring and adherence compared to methadone treatment. The document reviews several studies demonstrating the benefits of long-term agonist therapy over detoxification or short-term medication approaches for opioid
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyOPUNITE
This document summarizes a presentation about the Handle with Care program, which aims to help children who have been exposed to trauma. The presentation discusses how drug abuse and violence impact children, showing statistics on drug seizures and crimes in certain areas. It then describes the Handle with Care program, where law enforcement notifies schools of children who were exposed to a traumatic event so the school can provide trauma-informed support. School interventions discussed include therapy dogs, academic accommodations, and on-site therapy. The presenters emphasize that Handle with Care aims to help children succeed in school by providing trauma-sensitive support.
This document summarizes a presentation on advances in treating chronic pain and addiction. It includes:
- Presenters from PRIUM, American Airlines, and the Treatment Research Institute
- Learning objectives around chronic pain, psychosocial issues, Medicaid requirements for the ASAM Criteria, and implementing the criteria
- Disclosures from presenters about relevant relationships
- Overview of topics like the bidirectional relationship between physical and mental health, impacts of adverse childhood experiences, and the influence of stigma on substance use treatment
- American Airlines' workers compensation program which saw a 40% reduction in claims and lower pharmacy costs and disability after redesigning their approach to focus on early intervention and additional resources for employees with chronic
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
This document outlines an advocacy track presentation on activating communities to address prescription drug abuse. It provides biographies of the presenters and moderators and discloses any conflicts of interest. The learning objectives are to identify best practices for implementing CADCA's seven strategies for community change to impact prescription drug issues. It then provides examples of how various coalitions across the country are utilizing each of the seven strategies, such as providing education, enhancing skills, supporting communities, and changing policies.
This document summarizes a presentation on best practices for treating opioid addiction in the criminal justice population. It outlines the challenges of treatment in this population and identifies best practices for using medication-assisted treatment (MAT) and behavioral therapy. The presentation reviews key points from the ASAM National Practice Guideline, including that MAT is the standard of care for opioid use disorder and should be continued, initiated, or made available for inmates. Discontinuing treatment can be dangerous and contradicts evidence-based practices. The implications discussed are that the guideline supports higher quality care for inmates and a rehabilitative approach, while also helping to address the opioid epidemic.
This document summarizes presentations from public health officials in North Carolina and Northern Kentucky on community responses to the heroin epidemic. Key points include:
- Officials from North Carolina and Northern Kentucky outlined programs and partnerships implemented in their regions to address rising rates of opioid and heroin abuse, including treatment programs, harm reduction strategies, legislation, and education initiatives.
- Data presented showed increasing rates of overdose deaths, neonatal abstinence syndrome, and infectious diseases associated with intravenous drug use such as hepatitis C in Northern Kentucky.
- Community leaders and advocates in Northern Kentucky have worked to raise awareness, pass legislation to expand access to treatment, and establish prevention and support networks to address the heroin epidemic impacting the region.
1. Co-prescribing opioids and benzodiazepines poses serious health risks like respiratory depression and increased risk of overdose death. Delaware has high rates of prescriptions for these drugs.
2. Delaware's PDMP collects prescription data that can help identify patients and providers with troubling patterns of co-prescribing to reduce risks. Regular screening and urine tests can also help address misuse.
3. PDMP data analysis found that in 2013 over 12% of individuals in Delaware filled prescriptions for both drug classes, putting them at risk. The PDMP is a valuable tool to improve prescribing practices and detect misuse.
Rx16 prev wed_330_workplace issues and strategiesOPUNITE
This document discusses workplace issues related to prescription drug abuse and strategies for prevention. It begins with introductions of the presenters and moderators. The learning objectives are then outlined as understanding challenges of prescription drug abuse in the workplace, identifying prevention strategies, and describing programs available through SAMHSA. The document then covers topics such as the scope of prescription drug misuse among workers, risks to the workplace, prevention strategies employers can consider, and available resources from SAMHSA.
This document summarizes a presentation on managing morphine equivalent dose (MED) and identifying high-risk opioid use through "red flagging." It discusses how calculating MED at the point of sale can help identify unsafe dosages and decrease opioid prescriptions. It also evaluates different methods to screen for overdose risk, finding that simple opioid use thresholds to flag patients may not accurately target those most likely to experience preventable overdoses. The presentation aims to explain MED management, describe payer solutions that reduced opioid use, and identify more precise ways to intervene with highest-risk patients.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyOPUNITE
This presentation covered multi-media prevention strategies for issues like prescription drug overdoses. It discussed the CDC's digital Rx drug prevention campaign, best practices for digital messaging, and programs using expectancy challenge theory and media literacy education in schools. Presenters included representatives from the CDC, Media Literacy for Prevention, and the Hanley Center Foundation who discussed their work developing and implementing digital communications and single-session prevention programs.
The document discusses factors that can lead to transition from misuse of prescription opioid analgesics to heroin initiation. Through qualitative interviews with 31 individuals in New York City, four key factors were identified: 1) Use of high dose opioid analgesics; 2) Intranasal route of administration; 3) Development of physical opioid dependence; and 4) Dissolution of stigma regarding heroin in social networks. The trajectory toward heroin use was found to be similar regardless of whether opioid analgesic initiation was recreational or medical in nature.
The panel discussed two youth prevention programs - the Give Me a Reason voluntary drug testing program for parents and the This Is (Not) about Drugs prevention program implemented in schools. The Give Me a Reason program provides free at-home drug testing kits for parents to help prevent drug use among youth. The This Is (Not) about Drugs program uses a film and lesson plan to educate students about the risks of prescription opioid and heroin use with the goal of preventing first-time drug use.
Revised order rx16 pdmp wed_1115_1_eadie_2reilly_3hallvik_4hildebranOPUNITE
This document summarizes a presentation on a study examining how prescriber registration and use of a prescription drug monitoring program (PDMP) in Oregon impacted opioid prescribing patterns and patient outcomes. The study found that statewide opioid prescribing generally decreased over time, but prescribers who registered for the PDMP prescribed more after registering, especially those who used the PDMP most frequently. In contrast, prescribers who did not register prescribed less. Patients whose providers were all registered had lower overdose rates than those with some registered and some non-registered providers. The conclusions were that PDMPs may need refinements like mandatory use to optimize their impact on prescribing and outcomes.
View only rx16 prev tues_1230_1_duwve_2adams_3proescholdbell-sachdevaOPUNITE
This document summarizes a presentation on preventing hepatitis C and HIV outbreaks. It includes learning objectives about informing attendees of risks of infectious disease outbreaks related to injection drug use and describing collaborations between injury and infectious disease programs. The presentation features four speakers from Indiana and North Carolina public health departments and focuses on lessons learned from an HIV outbreak in Indiana linked to injection drug use.
This document summarizes a presentation on closing treatment gaps in the health care and criminal justice systems for opioid use disorders. It introduces the presenters and moderator and provides learning objectives focused on improving identification and treatment of opioid use disorders in health care settings and strategies for improving outcomes for frequently incarcerated individuals. Disclosures are provided for the presenters stating that they have no relevant financial relationships.
Web only rx16 len-tues_330_1_kougasian-sakacs_2niedermannOPUNITE
Three prosecutors presented on investigating and prosecuting homicide by a prescribing doctor. They discussed two criminal cases that resulted in convictions, including a case in New York where a doctor was convicted of manslaughter and reckless endangerment for overprescribing opioids. They identified challenges in investigating doctor-caused deaths and how they prepared evidence showing the doctor's conduct grossly deviated from medical standards. A prosecutor from Los Angeles then discussed prosecuting a doctor for murder based on killings that occurred during the felony of over-prescribing controlled substances. Undercover operations and search warrants provided evidence of the doctor's conduct.
Rx16 federal tues_200_1_gladden_2halpin_3greenOPUNITE
This document provides information about the emerging fentanyl overdose epidemic in the United States from the national and state perspectives. It discusses the rise in fentanyl-related overdoses and seizures from 2013-2014 according to data from various sources. The learning objectives are to explain the epidemiology of the rise in fentanyl overdoses, identify lessons from an Ohio investigation, and describe one state's experience. Recommendations include improving detection of fentanyl through testing and surveillance, expanding naloxone access, and long-term efforts to reduce opioid overdoses through prescribing guidelines and treatment expansion.
Linking and mapping PDMP data can provide several benefits but also faces challenges. Linking PDMP and clinical data allows for evaluating the impact of PDMP interventions on outcomes and prescribing decisions. However, obtaining permissions and data is difficult due to legal and resource barriers. Mapping PDMP data using GIS tools in Washington identified areas for targeting overdose prevention efforts by visualizing patterns in prescribing risks, treatment availability, and overdoses. Stakeholders used these maps to guide education and funding decisions. Sustaining these tools requires ongoing funding and expanding included data sources.
This document summarizes a presentation on drugs to watch including tramadol, hydrocodone, and naloxone. It includes:
- Disclosures from presenters declaring no conflicts of interest.
- Learning objectives focused on analyzing the impact of schedule changes for tramadol and hydrocodone, educating on tramadol dangers, and evaluating pharmacist perspectives on naloxone.
- Information presented on the drugs including their classifications, potencies, risks of abuse and addiction, and impacts of rescheduling hydrocodone and tramadol in California. Data showed decreased hydrocodone prescriptions but increased tramadol and overall opioid prescriptions, as well as increased over
This document summarizes a presentation on medication-assisted treatment for opioid addiction. It discusses the history of treatment approaches, including the development of methadone and buprenorphine maintenance therapies. Studies show that agonist therapies like methadone and buprenorphine are more effective at retaining patients in treatment and reducing illicit opioid use than non-medication approaches. While both methadone and buprenorphine are effective, buprenorphine has a safer side effect profile but its effectiveness may be limited by lower monitoring and adherence compared to methadone treatment. The document reviews several studies demonstrating the benefits of long-term agonist therapy over detoxification or short-term medication approaches for opioid
Web only rx16 len wed_200_1_augustine_2napier_3darr - copyOPUNITE
This document summarizes a presentation about the Handle with Care program, which aims to help children who have been exposed to trauma. The presentation discusses how drug abuse and violence impact children, showing statistics on drug seizures and crimes in certain areas. It then describes the Handle with Care program, where law enforcement notifies schools of children who were exposed to a traumatic event so the school can provide trauma-informed support. School interventions discussed include therapy dogs, academic accommodations, and on-site therapy. The presenters emphasize that Handle with Care aims to help children succeed in school by providing trauma-sensitive support.
This document summarizes a presentation on advances in treating chronic pain and addiction. It includes:
- Presenters from PRIUM, American Airlines, and the Treatment Research Institute
- Learning objectives around chronic pain, psychosocial issues, Medicaid requirements for the ASAM Criteria, and implementing the criteria
- Disclosures from presenters about relevant relationships
- Overview of topics like the bidirectional relationship between physical and mental health, impacts of adverse childhood experiences, and the influence of stigma on substance use treatment
- American Airlines' workers compensation program which saw a 40% reduction in claims and lower pharmacy costs and disability after redesigning their approach to focus on early intervention and additional resources for employees with chronic
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanOPUNITE
This document outlines an advocacy track presentation on activating communities to address prescription drug abuse. It provides biographies of the presenters and moderators and discloses any conflicts of interest. The learning objectives are to identify best practices for implementing CADCA's seven strategies for community change to impact prescription drug issues. It then provides examples of how various coalitions across the country are utilizing each of the seven strategies, such as providing education, enhancing skills, supporting communities, and changing policies.
This document summarizes a presentation on best practices for treating opioid addiction in the criminal justice population. It outlines the challenges of treatment in this population and identifies best practices for using medication-assisted treatment (MAT) and behavioral therapy. The presentation reviews key points from the ASAM National Practice Guideline, including that MAT is the standard of care for opioid use disorder and should be continued, initiated, or made available for inmates. Discontinuing treatment can be dangerous and contradicts evidence-based practices. The implications discussed are that the guideline supports higher quality care for inmates and a rehabilitative approach, while also helping to address the opioid epidemic.
The Buford Family church grew its membership by 20% in 2015, adding 30 new members to reach a total membership of 181. The church's average attendance was also higher than in previous years, exceeding 100% of its total membership. Additionally, the church saw increases in website views, online sermon views, live stream viewers, and tithes and offerings compared to previous years.
This document summarizes findings from interviews conducted as part of a study evaluating a chronic pain management pilot program for Medicaid patients in Rhode Island. Key findings include:
1) Patients reported that complementary and alternative therapies like acupuncture, massage and chiropractic care helped them better understand the relationship between stress and pain and provided an opportunity to build trusting relationships with providers.
2) Providers noted that the program allowed patients to receive hands-on care and personal connections that they may not receive otherwise due to lack of trust in the medical system and limited therapeutic relationships.
3) The program addressed transportation barriers by having some providers conduct home visits, improving access to care for patients with mobility issues.
4)
This document summarizes a presentation on health plan involvement in safe prescribing. It includes:
1) Presentations from medical experts on prescription drug abuse trends from medical examiner data and a tribal health system's safe prescribing program.
2) A discussion of health plan policies to reduce "red flag" medication combinations like opioids plus benzodiazepines through prior authorization, formulary changes, and provider restrictions.
3) Examples of one health plan's implementation of policies like restricting methadone prescriptions to pain specialists and removing carisoprodol from its formulary.
This document summarizes the opioid crisis in the United States from 2000 to 2014. It shows that the number of opioid-related overdose deaths more than tripled during this period, increasing from about 8,000 to over 28,000. Additionally, 7.9 million Americans aged 12 or older met the criteria for an illicit drug use disorder in 2013-2014 but only 20% received treatment. The document outlines actions by the Obama administration to address the crisis and increase funding for treatment. It emphasizes that stories can help reduce stigma and that recovery is possible through working together.
The panel discussion focused on how workers' compensation formularies can reduce opioid prescriptions. Formularies in states like Texas, Ohio, Oklahoma, and Washington were examined. The panel identified best practices for designing and implementing an effective formulary, and discussed stakeholders affected by formularies. Key factors in Texas' successful formulary were identified, as were lessons that can be learned from other states' experiences. The discussion addressed challenges like treating chronic pain if opioids are prescribed less and managing "legacy claims."
This document summarizes a presentation on linking and mapping prescription drug monitoring program (PDMP) data. It discusses the benefits of linking PDMP data to clinical data, including improving patient safety, evaluating prescribing decisions, and assessing the impact of PDMP interventions. It describes challenges with linking data, such as obtaining consent and negotiating data use agreements. It also discusses Washington State's MAPPING OPIOID AND OTHER DRUG ISSUES (MOODI) tool, which integrates PDMP data with other databases to map and target treatment and overdose prevention efforts at the community level.
1. Two states, South Carolina and Wisconsin, improved integration of PDMP data into electronic health systems by establishing connections between their PDMPs and various health IT platforms like EMR systems and pharmacy dispensing software.
2. States face challenges with PDMP integration like legal definitions of access, costs of integration projects, and establishing necessary agreements and user authorizations.
3. Florida operates drug surveillance systems through a medical examiners commission and PDMP. Analysis found declines in prescription opioid overdoses after implementation of legislative and regulatory interventions including a PDMP in 2011. However, heroin overdose deaths increased as some shifted to heroin.
This document discusses recovery ready ecosystems and recovery community organizations. It introduces presenters from Young People in Recovery and Hope House Treatment Track who will discuss interventions, prevention, and recovery programs. Examples of Young People in Recovery chapters, programs, and services are provided, including employment workshops, education workshops, housing workshops, and recovery support services. The document also discusses recovery community organizations and initiatives in Texas and Georgia, such as the Association of Persons Affected by Addiction in Dallas and the Georgia Council on Substance Abuse.
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessOPUNITE
This document discusses a presentation on pharmacy burglary, robbery, and diversion of prescription drugs. The presentation covers trends in prescription drug diversion, particularly those involving robbery and burglary of pharmacies. It identifies preventative measures to enhance pharmacy security and safety. Strategies to reduce pharmacy crimes are outlined. The offender perspective is examined based on interviews with convicted offenders. Routine activities theory is discussed as relating to suitable targets, capable guardians, and motivated offenders. Partnerships between regulatory agencies and law enforcement are emphasized as key to prevention efforts.
Web only rx16 treat-wed_1115_1_hudson_2badaOPUNITE
The document discusses treatment and outcomes of neonatal abstinence syndrome (NAS). It summarizes a presentation by two doctors on NAS treatment. It then describes a study examining outcomes of a palliative early treatment model for NAS at Greenville Memorial Hospital. The model involved early low-dose methadone treatment for opioid exposed newborns in a low-acuity nursery setting. Results showed lower length of stay, less weight loss and medical complications compared to national averages, with total hospital costs averaging $5,909 per case.
The document discusses the opioid crisis in the United States, including rising rates of prescription opioid misuse and abuse, as well as heroin use and overdose deaths. It outlines how research can help address this crisis through developing less abusable analgesics, expanding access to treatment medications like naloxone and buprenorphine, and exploring new treatment approaches such as immunotherapies and precision medicine targeting genetic factors. The National Institute on Drug Abuse is supporting these research efforts and working to disseminate findings to improve prevention and intervention programs.
This document discusses neonatal abstinence syndrome (NAS) and universal maternal drug testing. It provides background information on NAS including trends showing large increases in incidence and costs associated with NAS. It outlines objectives related to describing NAS trends, identifying legislative activities impacting NAS, describing family planning for women in substance abuse treatment, and explaining a hospital program using universal drug testing. The document then covers topics including NAS symptoms, incidence and geographic trends, costs of NAS, opioid use in women of childbearing age, unintended pregnancy rates, contraceptive use among opioid users, and maternal drug exposure sources.
Drug Treatment Courts: How America’s Most Trusted Alternative to Incarceration is Providing Hope in the Midst of the Rx Drug Abuse and Opiate Epidemic - Vision Session Presented by National Association of Drug Court Professionals
Rx15 le tues_330_1_daugherty-simons_2friedmanOPUNITE
This document summarizes a law enforcement initiative in Seattle, Washington to address pharmacy burglaries and robberies. A joint task force was assembled, using federal resources and statutes, to investigate over 150 burglaries and robberies across four states. By monitoring suspects' phones, identifying a distribution operation, and sending letters inviting suspects to cooperate, 48 individuals were identified and pleaded guilty. Sentencings included prison time, restitution, and firearm and drug seizures. The approach focused on changing criminal dynamics through respectful treatment of suspects and leveraging results through extensive press coverage. This strategy successfully eradicated pharmacy burglaries and robberies in Seattle.
This document discusses engaging the medical community on the issue of opioid use and abuse. It begins with introductions from Brian Fingerson, President of Kentucky Professionals Recovery Network, and Dallas Gay, Co-chair of the Medical Association of Georgia Foundation's "Think About It" Campaign. The speakers then review learning objectives about describing changing attitudes around prescription drug abuse, defining clinicians' roles in positively impacting the opioid epidemic, and demonstrating programs that are engaging the clinical community on appropriate opioid use and abuse.
This presentation covers about drug abuse and its prevention & the RA 9165. No copyright allowed. Please don't forget to like and write your comments below. Thanks and God Bless!
This document outlines guidelines for a safe space discussion on harm reduction approaches for sex workers and drug users. The objectives are to promote discussion of individual behaviors in social contexts, answer questions about risks of sex work and drug use, and explain harm reduction theory and how it can be applied in collaboration with feminist theory. Harm reduction aims to address risky behaviors by meeting people where they are at and providing non-judgmental support and resources to reduce harm.
This document summarizes the anatomy and process of a "No Refusal Weekend" where law enforcement, prosecutors, judges, medical professionals, and others coordinate to obtain blood samples from drunk driving suspects who refuse standard breath or blood tests after an arrest. Key aspects summarized are: coordinating the event weeks in advance; establishing procedures; securing necessary personnel like judges, nurses, prosecutors; publicizing through media; making arrests and obtaining search warrants from on-call judges for suspected drunk drivers who refuse testing; and having blood drawn and processed as evidence. The goal is to save lives by obtaining scientific evidence of intoxication or sobriety for both alcohol and drug-impaired drivers through this coordinated process.
FDA 2013 Clinical Investigator Training Course: Informed Consent and Ethical ...MedicReS
This document summarizes a presentation on informed consent. It discusses how informed consent is an ongoing process, not just a form. While forms are important, true informed consent requires an knowledgeable investigator who can have a genuine dialogue to ensure understanding. The investigator must design ethical studies, provide comprehensive information, allow time for reflection, and make sure participation remains voluntary. Ultimately, the integrity of the overall research process is most important to protect subjects and ensure consent is meaningful.
E, K, G, BZP, 2CB, 5MeO-DIPT...
“Party Drugs” such as Ecstasy, Ketamine and GHB have not gone away. However, there have been significant changes to purity and associated risks. As well, a proliferation of new substances are quickly appearing.
What are some of the current substances being used and the risk reduction messages we should be sharing, particularly with today’s youth?
We will look at:
Street Drugs --> Party Drugs --> NPS
Specific substances:
- What they are
- How they work
- Immediate risks
- Longer-term concerns
- Risk reduction strategies
The document provides information about a workshop on drug use, stigma, stereotypes and harm reduction. It outlines the goals of gaining understanding of the negative effects of stigma on people who use drugs and examining ways to reduce stigma and improve well-being. It establishes group guidelines for the workshop, including maintaining confidentiality and respecting different experiences. It then considers stereotypes related to drug use through pictures and a survey. Key aspects of drug-related stigma from individuals, institutions, internally and by association are examined. The implications of stigma for access to services, risk behaviors, self-worth and relationships are discussed. Factors influencing drug use including the continuum of use and drug, set and setting are briefly covered.
Powerpoint accompanying workshop session from the Homeless and Housing Coalition of Kentucky's 2013 conference. Presented by Tim Welsh
Many homeless individuals experience mental health problems that impact their ability to maintain stability.
This presentation will explore the issue of mental illness and help participants develop engagement and
intervention skills for working with individual who are experiencing a mental illness.
Forensic psychology is the application of psychological methods, theories, and concepts to the legal system. The history of forensic psychology in the United States began in the early 1900s as psychologists began testifying in court cases and working in correctional settings. Key events included the first use of psychological testing by police in 1916 and the first American psychologist qualifying as an expert witness in 1921. Forensic psychologists now work in a variety of legal contexts, including evaluating competency, insanity, risk assessment, and providing expert testimony.
This document describes a presentation on using data to drive down prescription drug abuse. It discusses how various agencies in Madison-Dane County, WI collaborated using multiple data sources to understand the local prescription drug problem and develop strategies to address it. Data on overdoses, deaths, hospital visits, and a community survey revealed high overdose rates and barriers to treatment. This informed a multifaceted initiative including a naloxone pilot program, Good Samaritan law, and increased treatment support. Policy changes at the state level further supported these efforts.
The document discusses classification of drugs of abuse. It states that in 2004 there were an estimated 6.7 million drug users in the Philippines, but by 2008 this had declined to 1.7 million users according to a government survey. Drugs are classified into several types including gateway drugs, depressants, stimulants, narcotics, hallucinogens, and inhalants. Each type is described along with examples. The document also discusses drugs used by indigenous people and asks process questions about drug abuse prevention.
This document discusses laws enacted as a result of parental advocacy around substance abuse issues. It summarizes Casey's Law, a law passed in Kentucky that allows involuntary substance abuse treatment. It was inspired by the death of Matthew Casey Wethington from a heroin overdose at age 23. The law allows parents, relatives or friends to petition the court to require someone to undergo treatment if they are unable to recognize their need for treatment due to impairment. It outlines the petition process, required evidence, evaluations, hearings, and possible outcomes including court-ordered treatment. The presenters aim to help advocates identify laws in their states, explain their components, and apply successful models elsewhere.
This document discusses various aspects of autopsies including the different types of autopsies, the autopsy procedure, certification of cause of death, and common mistakes in forensic pathology. It provides details on medico-legal autopsies including their aims, objectives, categories of cases that require an autopsy, and the steps involved in notification, investigation of circumstances, examination of the body, and laboratory tests. Key points covered are definitions of different types of autopsies, requirements for consent, certification of cause of death, and potential classical mistakes made in forensic pathology.
Over-the-Counter (OTC) and prescription drug abuse is a growing and dangerous problem, and as a retailer you can play a role in reducing and preventing it.
For additional info and resources on this topic visit www.helpingservices.org/otc.
Combating Human Trafficking in the USA and investigating it RightByron Olivere
This document provides an overview of human trafficking. It discusses the trafficker's methods, including grooming victims and controlling them through force, fraud and coercion. It also covers investigations, noting the importance of identifying victims, understanding trauma responses, and collaborating across agencies. Trafficking is very profitable with low risk. Reducing demand through customer deterrence is key to impacting the issue. Law enforcement training and resources need to increase to effectively address this crime.
Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingOPUNITE
This document discusses the role of health departments in preventing neonatal abstinence syndrome (NAS). It notes that NAS rates have increased significantly in recent years, disproportionately affecting women. Health departments engage in surveillance to monitor NAS trends, partner with other organizations, support treatment and recovery programs, and provide education to prevent NAS, which is entirely preventable. The document outlines specific strategies health departments use across these areas to address the opioid epidemic and protect maternal and infant health.
This document discusses strategies for reducing buprenorphine diversion and pill mills while improving access to treatment. It notes that limiting access to buprenorphine treatment is associated with increased diversion, while expanded access to quality treatment decreases diversion and overdose deaths. The document recommends educating prescribers, using medically-derived prescribing standards, ensuring adequate insurance coverage of safe prescribing practices, and addressing diversion risks for other controlled medications. It argues against onerous new regulations that could limit treatment access. The goal is to identify and support high-quality treatment while prosecuting criminal operations.
This document summarizes a presentation on youth performance-enhancing drugs and ADHD medication. It discusses trends in misuse of these substances among young people. The presentation is given by representatives from various organizations focused on prevention, health promotion, and substance abuse issues among youth and college students. The presentation covers types of performance-enhancing drugs and their potential side effects. It also discusses trends in attitudes towards these substances and risks of misuse. Strategies are presented for helping adolescents pursue their goals without these drugs. The document concludes by outlining plans for addressing misuse of ADHD medication among college students through education and collaboration between various stakeholder groups.
Web only rx16 pharma wed_200_1_hagemeier_2fleming_3vernachioOPUNITE
Community pharmacists are well positioned to help address the growing problem of opioid and benzodiazepine addiction but face challenges. Early identification of at-risk patients, supportive benefit structures, and intervention training could empower pharmacists. While many recognize their responsibility, behavioral engagement in prevention is often lacking due to practice barriers, lack of patient information, and fear of responses. Standardizing communication expectations and screening tools could help pharmacists better fulfill their role on the treatment team.
Rx16 federal wed_1230_1_kelly_2bohn-killorinOPUNITE
1) The National HIDTA Program provides assistance to law enforcement agencies in critical drug trafficking regions through 28 regional HIDTA programs. It facilitates cooperation among federal, state, local, and tribal law enforcement.
2) Each HIDTA program has an executive board that identifies threats, develops strategies, and requests funding for initiatives. It brings together over 7,400 federal agents, 15,700 state and local officers, and 500 agencies across the country.
3) In response to the opioid epidemic, HIDTA employs law enforcement targeting of heroin and fentanyl trafficking, public health prevention efforts, and training on investigating heroin organizations. It has committed additional funds to enhance intelligence sharing and public health partnerships.
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Web only rx16 len wed_1230_1_daugherty_2baier-haas
1. Drug-Related Deaths: Investigation,
Prosecution and Review Strategies
Presenters:
• Patricia Daugherty, JD, Assistant District Attorney, Milwaukee
County (WI) District Attorney's Office
• Michael Baier, Overdose Prevention Director, Maryland
Department of Health and Mental Hygiene
• Erin Haas, MPH, Overdose Prevention Local Programs Manager,
Maryland Department of Health and Mental Hygiene
Law Enforcement Track
Moderator: Connie M. Payne, Executive Officer, Department of
Specialty Courts, Kentucky Administrative Office of the Courts, and
Member, Operation UNITE Board of Directors
2. Disclosures
Michael Baier; Erin Haas, MPH; Patricia
Daugherty, JD; and Connie M. Payne have
disclosed no relevant, real, or apparent personal
or professional financial relationships with
proprietary entities that produce healthcare
goods and services.
3. Disclosures
• All planners/managers hereby state that they or their
spouse/life partner do not have any financial
relationships or relationships to products or devices
with any commercial interest related to the content of
this activity of any amount during the past 12 months.
• The following planners/managers have the following to
disclose:
– John J. Dreyzehner, MD, MPH, FACOEM – Ownership
interest: Starfish Health (spouse)
– Robert DuPont – Employment: Bensinger, DuPont &
Associates-Prescription Drug Research Center
4. Learning Objectives
1. Identify strategies for investigating and
prosecuting drug-related homicides.
2. Explain how multiple tools can be utilized to
build prosecutable cases.
3. Describe how Overdose Fatality Review can
make recommendations for law, policies and
programs.
6. Financial Disclosure Statement
ADA Patricia Daugherty has disclosed no
relevant, real or apparent personal or
professional financial relationships with
proprietary entities that produce health care
goods and services.
7. Learning Objectives:
1. Identify strategies for investigating and
prosecuting drug-related homicides.
2. Explain how multiple tools can be utilized
to build prosecutable cases.
8. Intro
• Assistant District Attorney for 8 years
• First 2 years as Violent Crime/Felony Drug ADA
• Last 5+ assigned to WI HIDTA
– Focusing on RX Drug cases, Pharmacy Robberies,
Higher-level heroin trafficking, and overdose
death prosecutions
9. Overview
• Overdose Stats/Why These Cases Matter
• Investigative Techniques & Building a Case
• Use of Illustrative Case Studies
11. 2013: 38,851 PEOPLE DIED FROM
DRUG OVERDOSES IN THE US
…But what about in Wisconsin?
12. Milwaukee County
• 2009: 127 Fatal Drug Overdoses
• 2014: 249 Fatal Drug Overdoses
• A 96% increase in deaths in 5 years
• Approx. 3.5x the number of traffic deaths
13. 38,851 US Deaths-2013
• Given the US POP 12.3 deaths/100,000
• Milwaukee has 956,406 people
• Meaning our OD death rate = 26
deaths/100,000
14. Legal Standard
• So-Called “Len Bias” Homicides
• State Statutes Differ…so confer with your local
prosecutors about the law in your state
• I’ll use Wisconsin law as an example, but the
basics should be the same…
15. First Degree Reckless Homicide
• 940.02(2)a
• Whoever causes the death of another
– By manufacture, distribution or delivery of a
controlled substance (Sch. I or II or analog or
Ketamine/ flunitrazepam) if another human being
uses the controlled substance and dies as a result
of that use.
16. Len Bias Homicide
• We have to prove:
– Target delivered a substance
– The substance was a CS
– Target knew it was a CS
– Victim used that CS
– And died as a result of that use
• Died as a result = Drug was a substantial factor
in the death
17. Conclusion
• Again, your local laws likely differ
• However, at the core, you will have to prove
that:
1. Your target delivered a drug
2. Your victim used that drug
3. Your victim died from using that drug
19. OVERVIEW:
Signs of Overdose
• Presence of Drugs/Drug Paraphernalia
• Deceased has drug history
• Evidence on phone (drug-related texts)
• Witnesses report that deceased was snoring
loudly prior to death
– Loud Snoring is not a positive sign, it is a sign of
respiratory distress!
• Physical Appearance/Evidence…
20. Foam Cone
• Opiates = Central Nervous System (CNS)
depressant
• Decrease in heart rate and breathing fluids
gathers in lungs
• People drown in their own fluids.
• “Foam Cone”
25. EVIDENCE RECOVERY OVERVIEW
• Scene Search: If suspected OD death,
toxicology not back for 10-12 weeks
• Person and Area
– Include garbage and ashtrays
– Friends/Family may have “cleaned” area
• Vehicles
• SEIZE PHONES and/or obtain numbers
26. First Steps
• Treat an overdose scene as a homicide scene from
the beginning.
• All too often, evidence is lost because the scene is
not secured or properly processed.
27. First Steps At The Scene
• Photograph and document the scene as you
would with ANY homicide case.
• Take photos of:
• the body as it was found and then once moved
• Frequently, items of evidence are located underneath
the body (baggies, cookers, etc.)
• The scene (overalls) before, during, and after
search
28. First Steps
• Look for drug packaging (corner cuts, etc.)
• Check trash, toilet bowl, etc.
• It is possible to do a quantification of a drug sample to
determine the “cut” of the drug. This can later be
compared against any drugs you might obtain from
your target via a controlled buy.
• Bag each item separately & wear gloves
• Search everywhere
29. Don’t Advertise…
• Consider NOT having squads visible on the
street…may try to do a CI buy later.
• Better chance of successful buy if the target
isn’t aware of the death
31. First Steps
• Look for method of ingestion
•Syringe, mirror with residue, etc.
• Any relevant paraphernalia
•cooking tins, hose clamps/ grinders, etc.
• Process items for fingerprints/ DNA
32. Packaging Material
• It is possible to have the packaging analyzed
for prints/DNA
• Also possible to have residue drug-tested
• If DNA/Prints are absent, the kind of packaging
used can connect a death to your target
– i.e. the target sells in plastic corner cuts, etc.
33. SYRINGES
• Crime Lab can do a chemical
test/wash for heroin or substance
used
• We can also submit for
fingerprints/DNA as necessary.
34. Narcan
Naloxone Hydrochloride
• Naloxone prevents and/or reverses the effects of
opiates, especially the respiratory depression
• Needle exchange provides free doses of Narcan
• Does NOT remove the opiate from the system
and users can “rebound” into an OD
35. Narcan
• Look for evidence of Narcan use at the crime
scene
• This may be evidence that your victim was
with someone prior to their death.
• Rebound ODs are common
• It can also impact your timeline
36. Scene Search:
Electronic Devices
• More on this later, but these are extremely
important to take during your search.
• Look for cell phones, tablets, and other
devices (watch phones, Google Glass,
beepers?)
• If Apt. complex or surrounded by businesses,
look for surveillance footage. May capture
video of supplier and/or car.
37. Searches: Conclusion
• Remember: The scene may have been
cleaned.
• Look in common area dumpsters, etc.
• If applicable, seek consent to search the
personal property (purses/bags/cars) of
anyone on scene.
• They may try to remove relevant evidence
from the scene.
39. INTERVIEWS OF WITNESSES
Start Immediately
Record whenever possible.
Build a 24-48 hour timeline
Gather historic information on
Victim
40. Witnesses
• What did they see? Did they witness the
buy/use? Who else was present? Who does
Vic use with? When did they last see Vic
prior?
• Are they (Witness) a user? Track marks? Did
they go with the Vic to get drugs?
When/Where? Can they do a buy?
• Obtain their phone #’s and consent to search
if they are willing.
41. Interviews….
• Knowledge of Victim’s Use (Snort, IV, etc.)
• Knowledge of drug combinations
• Illicit
• Prescription
• Victim’s Previous Overdoses
• Do they know Vic’s Source(s) of supply, friends
– phone numbers, street names, Facebook,
etc.
• Who are Vic’s doctors, pharmacies
42. CREATE TIMELINE
• Interviews
• Telephone Records
• Receipts
– gas, restaurant, bank…
• Surveillance Videos
– often deals at public places
• Physician/Pharmacy Records
43. Interviewing The Suspect
• Try to be as specific as possible about their
dealings with victim. When and where did the
transaction occur? Amount bought and $.
• Did they middle the deal? Co-user?
• You don’t have to tell them that victim is deceased
if they are unaware.
• Will they consent to a search of their phone,
house, car, etc.?
44. Interviewing The Suspect
• Ask about their business (how many people
do they supply, phone numbers used, how
long selling/using, how do they package their
drugs)
• Who is their supplier? Photo arrays if relevant.
How much do they get from supplier and how
often? How is contact made? How is payment
made?
• Are they willing to cooperate if approved?
46. First Steps
• If you have a suspect, it is advantageous to
attempt to do a recorded controlled buy ASAP.
• This will give us a case against him while we wait for
the ME’s determination (and possibly keep him in
custody)
• It will be extra leverage in negotiating a resolution
• Can obtain a contemporaneous sample of dealer’s
drug (if not RX) which can be compared with the cut
from your scene of death. Can be like a fingerprint.
47. First Steps
• You can get the suspect to confirm the
delivery in the overdose case
• For ex: “Do you have any of that stuff you gave me
and [the deceased] on Sunday night? It was really
good.”
• It is best to do this ASAP, preferably before
your target knows the victim has died. That
tends to spook them a bit.
48. First Steps
• If your victim utilized text messages to contact
their supplier, consider using the victim’s cell
phone to send messages to the target
• You may be able to set up a buy/bust without
using a CI
49. Buys
• If your CI has a regular pattern of ordering
from their supplier, it might be
advantageous to have them do an order up
so as to not raise the supplier’s suspicion.
• Heroin users are creatures of habit and their
suppliers will become suspicious if they miss
too many “appointments.”
• Be aware of this if trying to work someone after you
have had them in custody
50. Buys
• If you do get a buy—Video and Audio Record
it. This is a homicide case. The jury will not
be sympathetic to excuses
• On recording, try to have CI reference prior
deal (date)
• This buy can help us establish patterns
• Working off same phone # as dealer in OD
• Drugs are packaged in same material (signature, etc.)
• It is also good leverage
51. Tying your suspect to the phone
used in the homicide is crucial
•Buys can help with this
•Better than “subscriber info” because it
puts the target in physical control of the
device.
52. Can’t Get a CI/Buy
• If you can’t get someone to do a buy or it
doesn’t work out:
• Consider garbage pulls, surveillance of
target/pretext stop when we believe he has
scored, etc.
• If it is a known target or we have a phone number,
check with HIDTA to see if they have had any
contact or intel.
53. Can’t Get a CI/Buy
• With Target’s phone records, develop “Top 10”
list of customers
• Build case on customers (traffic stops, drug
paraphernalia, etc.)
• Flip the customers on their supplier
54. Court Orders and Records
This section will detail the kinds of
orders/evidence/data we can get
The following section will discuss what
analysis is available once we lawfully obtain
the evidence/records/data
56. Cell Phones
• In many cases, you will locate cell phones at
the scene of the death.
• Phones can be invaluable in building your case
and identifying your suspect(s)
57. Phones & Timelines
• Once we ID a target who delivered drugs to
our victim:
• We want to show that the victim did not obtain
also drugs from ANOTHER source
• Phone records can show that the victim did not
have drug contacts AFTER getting drugs from the
target.
58. Phone Searches
• Often, you may need to get a warrant to
search the victim’s telephone.
• I recommend a sealing motion/order
59. Passcodes
• HIDTA, etc. can defeat some passcodes, but
not all. THIS IS ALWAYS CHANGING
• Ask the family/friends if they know the
passcode
• Importance of preservation letters
60. First Steps
- Send preservation letters for text messages and
cell tower information ASAP
- Obtain SW to search any relevant phone
recovered and obtain subpoena/warrant for call
records and subscriber information as needed
- Request that records be provided with a certification
from the phone company. This will save a lot of
headaches at trial.
61. Content
• Supplier’s phone/phone records will reveal
their other contacts (customers, etc.) from the
incident date. You can locate and interview
those people to establish your target’s
possession of the target phone
• The physical phone search is your best shot at
getting useful text message content.
63. Court Orders For Records
• Your state statutes will differ, but…
• The phone company will require a court order to
produce these records.
• What follows references WI statutes, but is
applicable to all orders
64. Text Messages…
• Call company immediately
• How long are messages kept ?
• Preservation Letter (on letterhead)
• Need a warrant for text content/cell tower
data
65. Retention Periods Vary
Some companies don’t keep text
content at all, while others keep it
for only a few days
69. Other Orders
• GPS on your suspects’ cars.
• Trap/Trace/Cell Tracker
• Warrant for computers
• Warrant for Social Media
• Order for PDMP
70. Cell Tracker
• Track the location of the phone (similar to
a ping order)
• Useful if you know the number used by
your dealer, but not their location/identity
71. GPS
• A warrant allowing for the
installation/monitoring of a
tracking device
• Can lead to the identification of
your target’s stash houses
• Can also show target travelling to
re-supply
72. Social Media
• Many social media platforms have chat and/or
email features
• Won’t be accessible to the public
• Warrant for Content
• Preserve publically available social
media/YouTube content
73. PDMP Records
• PDMP = Prescription Drug Monitoring
Program
• Basically, every time a RX for a Scheduled CS is
filled, a record is transmitted to a state
database
• We can get that info with a valid court order**
** You may not need an order in your state
79. • 7 different
substances
• Don’t have to
prove Heroin =
Sole cause, only
SUBSTANTIAL
FACTOR in the
death
80.
81.
82. • Presence of Morphine & 6-MAM =
Heroin OD
• Nothing but Heroin metabolizes into
6-MAM
• Codeine frequently found too
83.
84. EVEN WITHOUT 6-MAM, WE CAN
STILL PROVE IT WAS HEROIN
…a look at “Morphine” overdoses
85.
86.
87.
88. • Morphine OD NOT Heroin OD
• Absence of 6-MAM, but presence of
Morphine
• We prove the Morphine came from
heroin through other evidence
• Testing of drug paraphernalia, text messages,
etc.
89. Case Studies
• Not just “war stories”
• Included here to illustrate implementation of
the strategies discussed earlier
**All defendants not yet convicted are
presumed innocent of all charges
90. State v. Defendant TJ
• Two Deaths (VD. and TS.)
• 25 days apart
• Both “Morphine” ODs
91. Implementation of Investigative
Strategies
• Store (Walgreens) Security Footage
• ALPRS
• Phone Dumps
• Phone Mapping
• Jail Calls
• Utilities Searches
• Phone Frequency Charts + Common Calls
• Facebook
92. TS Death
• Early December 2013
• Uncle visiting his Nephew and Nephew’s
friend in the dorms
• Bought heroin from “Playboy” at 414-841-
6135
• Nephew & Friend testified at trial for the State
• “Playboy” only sold $50 bags and only sold
knotted topped baggies
93. TS Death
• Deal took place at Walgreens in parking lot
• Video showed Playboy arriving in dark 2 door
car with hubcaps
• We brought in a car expert who could ID it as
a late 90’s Olds Achieva.
• ALPRS found a car listing to TJ.
96. Witness IDs
• Both Nephew & Friend ID Def. as the supplier
that night known to them as Playboy
• Both ID his phone number (burner phone) as
414-841-6135
• Phone records from Nephew & Friend show
hundreds of calls to this number in the
months leading up to death…corroborating
their connection to Playboy/ID of Def.
97. Victim VD
• About 25 days later, VD is found deceased
• Body not found for about a week
98. VD
• Military Vet, injured overseas…became
addicted to pain pills at the VA
• At the VA, met another Vet (AB) who would
later middle the fatal deal between VD and
Def. TJ
99. VD was found approximately 7 days after her
death, by a roommate…
100. Date of Death
• ME can give an approximation, but not 100%
• Look at phone patterns:
– She sent 100s of texts every day, but they stopped
entirely within an hour of her contact with TJ.
Same with Facebook
– Missed calls started piling up at the same time
• Med taker…pill calendar--SMTWTHFS
101. VD
• Phone Dump Texts between VD and ABRemember: College witnesses said their dealer only sold $50
bags. Same thing here.
Additional texts set up AB picking VD up
AB’s phone records show her calling her dealer thereafter
102. VD
–AB provided information on her heroin
supplier known to her as “Memphis” at phone
number 414-722-5218
• Dump of her phone Contact = Def. TJ
• Admitted to buying the heroin from Def. TJ at
his residence
104. Utilities
• WE Energies records list TJ as the subscriber
for the address ID’d by AB as the location of
the deal
• Mapping puts the “Memphis” phone in that
area at the time of the contact with AB/VD
106. Two Phones
• Two Different Phones were used in the two
deaths.
– “Playboy” is 841-6135
– “Memphis” is 722-5218
• 18 common contacts
• AB’s number in both phones
• CLEARLY not two unrelated #s!
107. Two Phones
• Also showed that there were numbers that
would call 1 phone, get no answer, and then
call the other
• Clearly connected, notwithstanding both are
“burner” phones
108. Jury Trial
• West Allis and UW-Milwaukee witnesses
testified (proffer agreements)
• Expert Witness testified on suspect vehicle
• Officer/Investigators testimony
• HIDTA Analyst – cell phone mapping
• West Allis Analyst – frequency and common
calls
• Medical Examiner testified to cause of death
113. Take Aways…
• Shows that lots of little things can add up to
build a very solid case
• When you have “users” who will testify, juries
want CORROBORATION…
• Why should they believe this “heroin addict”?
• Because all of these phone records, utility
records, store video, cell tower data, etc.
backs them up.
114. Email me if you want…
• “Cheat Sheet” for OD investigations
• Longer “Best Practices” Guide
• Telco Info & Retention Periods
• Sample Preservation Letter
• Sample WI Warrant for Cell Records
116. CONTACT INFO:
A.D.A. Patricia I. Daugherty
Milwaukee County District Attorney's Office
T: (414) 278-5183
Patricia.Daugherty@da.wi.gov
Thanks again to Det. Nick Stachula
117. Overdose Fatality Review
in Maryland
Michael Baier
Overdose Prevention Director
Maryland Department of Health and Mental Hygiene
Erin Haas, MPH
Overdose Prevention Local Programs Manager
Maryland Department of Health and Mental Hygiene
118. Michael Baier has disclosed no relevant, real or apparent
personal or professional financial relationships with
proprietary entities that produce health care goods and
services.
Erin Haas, MPH, has disclosed no relevant, real or
apparent personal or professional financial relationships
with proprietary entities that produce health care goods
and services.
119. Learning Objectives:
1. Identify strategies for investigating and prosecuting
drug-related homicides.
2. Explain how multiple tools can be utilized to build
prosecutable cases.
3. Describe how Overdose Fatality Review can make
recommendations for law, policies and programs.
120. Overdose Fatality Review Background
• 2011-2012: State tracks significant rise in OD deaths (Rx
opioid & heroin-related)
• Jan. 2013: Maryland Opioid Overdose Prevention Plan
o Implement Prescription Drug Monitoring Program
o Surveillance of problematic prescribing/dispensing
o Overdose education & naloxone distribution
o Continue access expansion for opioid replacement
therapy (methadone & buprenorphine)
o Local overdose prevention plans
o Pilot local overdose fatality review teams (LOFRT)
121. Overdose Fatality Review Overview
• Modeled after existing mortality review programs
(Child Fatality Review)
• Multi-agency/multi-disciplinary team assembled at
local (county/Balt. City) level to conduct
confidential reviews of overdose death cases
• Goal to prevent future deaths by:
o Identifying missed opportunities for prevention and gaps in system
o Building working relationships b/t local stakeholders on OD
prevention
o Recommending policies, programs, laws, etc. to prevent OD
deaths
o Informing local overdose prevention strategy
122. Overview Ctd.
• Implementation supported by 2013 DOJ Harold Rogers PDMP grant
• DHMH interagency collaboration to provide T/A & data to teams,
including:
o Death investigation records from Office of Chief Medical
Examiner
o Confirmed decedent info from death certificate
o Coded toxicology data
o Substance use disorder treatment records from statewide
database
• Team members bring info from respective agencies about decedents
to inform review
• 2014: 3 Pilot Teams → Baltimore City, Cecil County, Wicomico
County
• Currently 18 teams active (out of 24 total jurisdictions)
• 200+ cases reviewed to date
123. OFR Legal Authority
• Pilot phase: Existing state “medical review committee” statute
provided authority for local health depts. to establish teams
• OFR law effective October 2014:
– Direction on team structure and operations (membership,
goals, etc.)
– Requires healthcare providers & gov. agencies to provide
decedent records on request from team
– Civil liability protection for team members and those that
provide information
– Confidentiality requirements
– Establishes DHMH oversight and team reporting
requirements
125. Sample Case: Mr. Leighman
• OCME Data:
– 48 AA Male
– DOD: 10/1/2015
– COD: Heroin Intoxication
– Autopsy? Yes
– Other substances in toxicology screen: Benzoyle,
Cocaine, Codeine, Freemorphine, Morphine
– Manner of death: undetermined
– Location of residence: Somerset County
– Location of incident: Wicomico County
126. OCME Activity Comments
Stewart Gilbert Leighman, B/M, DOB 7/29/1967, lives in a wooded area in a
small tent near Salisbury, Wicomico County, Md. on 10-1-15 at 0830 hrs. He
met his girl friend, Lesha in Salisbury, Md. And they walked to PRMC where
Lesha visited with her mother and apparently borrowed some money from her
mother, thirty dollars of which she gave to Mr. Leighman. The two parted ways
at 1200 pm and Mr. Leighman said he would see her back at the tent. Lesha
did not return to the tent because of the heavy rain, instead, she called Robert
Lewis, Mr. Leighman’s cousin, to check on him. Mr. Lewis went to the tent at
1845 hrs. And discovered Mr. Leighman lying on his back in the tent with just
his shorts on, he was unresponsive and Mr. Lewis could not awaken him. Mr.
Lewis called 911 and he says he started CPR. Arriving EMS found him in
asystole and transported him to PRMC ED. He was given life saving treatment
to no avail. He was determined dead at 1942 hrs. Mr. Leighman has a history of
Diabetes and stomach problems. He has a history of Cocaine use and Heroin
use. The family requested Smith funeral home and they were called and
agreed to respond. OCME was notified of this case and autopsy was ordered
by the F.I.
127. Sample Case : Mr. Leighman
• EMS: day of death only
• Hospital: Yes (multiple ER visits for stomach pain)
• Social Services: Yes (food stamps and MA)
• Sherriff's Office: Yes
• State’s Attorney’s Office: Yes
• Court System: Yes (3 open cases, all drug related)
• Community supervision: Yes
• Drug Treatment: Yes
• Pain Management: Unknown
• Pharmacy records: Unknown
128. Team Conclusions: Mr. Leighman
• Mr. Leighman had open cases in different
bordering counties on the Eastern Shore of MD
• Spent the better part of the past 25 years
incarcerated
• Lived in 3 different counties, homeless at the
time of death, did not have a good system of
care
• No known referrals for Diabetes case
management
• No cell phone made it difficult to provide follow
up care
129. Team Conclusions: Mr. Leighman
• Risk factors: transience/homelessness,
history of addiction, co-occurring chronic
illness, older adult, possible long period of
abstinence
• System-level implications: need for improved
coordination of healthcare services for
transient population, overdose prevention
and substance use disorder treatment access
for incarcerated individuals, community
naloxone trainings targeting homeless
population
130. Reach Points/Interactions
Agencies Total Of Cases Percentage
Community Supervision 46 27%
Court System (Drug Court, Family Court, etc.) 37 22%
Department of Social Services (inc. Human Services) 60 35%
Department of Juvenile Services 4 2%
Detention Center 30 18%
Substance Use Disorder Treatment 92 54%
Emergency Medical Services (EMS) 107 63%
Hospital 64 37%
Insurance Coverage 13 8%
Mental Health Treatment 44 26%
Pharmacy 20 17%
Law Enforcement 143 84%
Syringe Services Program Baltimore City 14 8%
State's Attorney's Office 53 31%
Total interactions: 727 171 cases
131. Notable LOFRT Findings
Decedent factors:
• Prior overdose(s)
• DUI/DWI
• Suicide attempts/ideation
• Intimate partner violence (as victim or perpetrator)
• Heavy social services & criminal justice involvement
• Poly-pharmacy
• Pain management
• Occurrence of trauma just before death (loss of a loved one, struggles with
child custody, etc.)
• Older drug users with many co-occurring chronic health issues
• Involvement w/ treatment services, but poor care coordination & follow
through on referrals
Incident factors:
• Deaths at home, often w/ family/housemates at home too
• Hotels and motels
• Recent release from jail
• Alcohol along w/ opioids in COD
132. Statewide Impacts/Outcomes to Date
Local:
• Training organization staff to use naloxone (Tx providers, LE, etc.)
• Increased attention to care coordination and referrals b/t service providers
• Changes to intake questionnaires to include questions about overdose history
• Promoting addiction education and assessment at all levels of the
organization
• More direct outreach to families on overdose prevention and wraparound
services by those that serve people at risk of overdose
State:
• System to monitor SUD provider reporting of patient OD deaths
• Research project investigating suicide overdose deaths
• Potential project to identify and provide services to decedents’ family
133. Considerations for Team Development
• Identify legal authority
• Important to have multidisciplinary approach
• Utilize existing relationships
• Heavy reliance on collaboration
• Encourage ongoing participation from members
• Social-ecologic vs. individual focus
• Task oriented
• Establish processes and expectations early on
• Consistently and frequently review goals of the team
• Formalize your observations and recommendations
• Allows for agencies to improve their practices based on
evidence
134. Drug-Related Deaths: Investigation,
Prosecution and Review Strategies
Presenters:
• Patricia Daugherty, JD, Assistant District Attorney, Milwaukee
County (WI) District Attorney's Office
• Michael Baier, Overdose Prevention Director, Maryland
Department of Health and Mental Hygiene
• Erin Haas, MPH, Overdose Prevention Local Programs Manager,
Maryland Department of Health and Mental Hygiene
Law Enforcement Track
Moderator: Connie M. Payne, Executive Officer, Department of
Specialty Courts, Kentucky Administrative Office of the Courts, and
Member, Operation UNITE Board of Directors
Editor's Notes
If narcan in system and take narcotics will overdose more quickly
24 hour time line
Who they were last seen with, what were their activities during last 24 hours..
Prescription drugs
who are doctors
were they ordering over the internet
are they stealing from friends or relatives
related property crimes
worthless checks
stolen cd’s
burglaries
Medical charts and pharmacy records (Walgreens printout stapled to bag) can be used to show that the bad guy had knowledge that the mixture could be fatal.
???
Could go more into the findings and explain how this can inform law enforcement investigations
Opportunity to identify more social-ecological reasons for overdose